Patent details

EN | LT

LT - Use of 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine for the treatment of non small cell lung carcinoma with acquired resistance to epidermal growth factor receptor (EGFR) modulators.

EN - Use of 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine for the treatment of non small cell lung carcinoma with acquired resistance to epidermal growth factor receptor (EGFR) modulators.

Legal status

Patent not validated

Bibliographic data

Indications of the International Patent Classification (IPC)
(51)	INT.CL.	A61K 45/06
		A61P 35/00
		A61K 31/5377

European patent
(11)	Number of the document	2259800
(13)	Kind of document	T
(96)	European patent application number	09716778.7
	Date of filing the European patent application	2009-03-04
(97)	Date of publication of the European application	2010-12-15
(45)	Date of publication and mention of the grant of the patent	2014-05-07
(46)	Date of publication of the claims translation

PCT application
(86)	Number	PCT/EP2009/052564
	Date	2009-03-04

PCT application publication
(87)	Number	WO 2009/109605
	Date	2009-09-11

Priority applications
(30)	Number	Date	Country code
	08152326	2008-03-05	EP

Inventors
(72)	GARCIA-ECHEVERRIA, Carlos, CH MAIRA, Sauveur-Michel, FR

Grantee
(73)	Novartis AG, Lichtstrasse 35, 4056 Basel, CH

Title
(54)	Use of 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine for the treatment of non small cell lung carcinoma with acquired resistance to epidermal growth factor receptor (EGFR) modulators.
	Use of 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine for the treatment of non small cell lung carcinoma with acquired resistance to epidermal growth factor receptor (EGFR) modulators.